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In the colon, a sophisticated balance between immune reaction and tolerance is abso-
lutely required. Dysfunction may lead to pathologic phenotypes ranging from chronic 
inflammatory processes to cancer development. Two prominent modulators of colon 
inflammation are represented by the closely related cytokines interleukin (IL)-12 and IL-23, 
which initiate adaptive Th1 and Th17 immune responses, respectively. In this study, we 
investigated the impact of the NADPH oxidase protein p47phox, which negatively regu-
lates IL-12 in dendritic cells, on colon cancer development in a colitis-associated colon 
cancer model. Initially, we found that IL-12−/− mice developed less severe colitis but are 
highly susceptible to colon cancer. By contrast, p47phox−/− mice showed lower tumor 
scores and fewer high grade tumors than wild-type (WT) littermates. Treatment with 
toll-like receptor 9 ligand CpG2216 significantly enhanced colitis in p47phox−/− mice, 
whereas tumor growth was simultaneously reduced. In tumor tissue of p47phox−/− 
mice, the IL-23/IL-17 axis was crucially hampered. IL-23p19 protein expression in tumor 
tissue correlated with tumor stage. Reconstitution of WT mice with IL-23p19−/− bone 
marrow protected these mice from colon cancer, whereas transplantation of WT hema-
topoiesis into IL-23p19−/− mice increased the susceptibility to tumor growth. Our study 
strengthens the divergent role of IL-12 and IL-23 in colon cancer development. With the 
characterization of p47phox as a novel modulator of both cytokines our investigation 
introduces a promising new target for antitumor strategies.
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inTrODUcTiOn
Maintenance of a subtle balance of immune responses in the colon is required to prevent excessive 
reactions to commensal microbes while at the same time providing effective recognition and removal 
mechanisms for invading pathogens. This comprehensive task is fulfilled by colon-resident innate 
immune cells, such as macrophages and dendritic cells (1–4). Unbalanced immune responses may 
result in autoimmune reactions (excessive responsiveness) or as sequelae of chronic inflammation to 
tumor initiation (excessive tolerance) on either end of the spectrum. Initiation of a specific adaptive 
Abbreviations: ACF, aberrant crypt foci; AOM, azoxymethane; DSS, dextrane sodium sulfate; IL, interleukin; i.p., intraperi-
toneal; ODN, oligodeoxynucleotide; PBS, phosphate-buffered saline; STAT, signal transducers and activators of transcription.
Table 2 | scoring system for tumor growth.
number of tumors score size (average diameter) score
0 0 0 0
1–2 1 Just detectable 1
3–5 2 1/8 2
6–8 3 1/4 3
9–12 4 1/2 4
≥13 5 ≥1/2 5
Table 1 | scoring system for inflammation (colitis).
Parameter score
0 1 2 3
Thickening of the colon Transparent Moderate Marked Non-
transparent
Changes of the vascular 
pattern
Normal Moderate Marked Bleeding
Fibrin visible None Little Marked Extreme
Granularity of the 
mucosal surface
None Moderate Marked Extreme
Stool consistency Normal + solid Still 
shaped
Unshaped Spread
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immune response is governed by secretion of polarizing cytokines 
by activated antigen-presenting cells. The polarizing interleukin 
(IL)-12 family members IL-12 and IL-23 share the common 
subunit p40, which is linked to the subunit p35 to form IL-12 or 
to the subunit p19 to form IL-23 (5, 6). In recent years, an intense 
debate about both cytokines has arisen with respect to their appar-
ently opposing roles during tumor development. Whereas IL-12 
initiates tumor rejection via polarization of IFNγ-producing Th1 
cells, activation of natural killer, and cytotoxic T cells (7–9), IL-23 
promotes tumor progression. IL-23 induces IL-17 and IFNγ 
secretion of innate lymphocytes and T helper cells in the colon 
(10, 11). It has been demonstrated that IL-23 is highly upregu-
lated in human tumor tissue from different organs (12). In human 
colorectal cancer, the expression of IL-23, its receptor (IL-23R), 
and IL-17 correlates with a poor prognosis (13–15). Human data 
have been confirmed in tumor models of mice (12, 16, 17). In 
a very recent publication, Teng and colleagues showed that in 
an equilibrium phase, characterized by residual, not-eliminated 
tumor cells, the activation and regulation of IL-12 and IL-23 seem 
to be important for the progression of malignant tumors (18). In 
this situation, the balance between IL-12 and IL-23 in the tumor 
microenvironment is regulated by the transcription factor STAT3 
and possibly sphingosine-1-phosphate (19, 20).
A shift of the IL-12/IL-23 balance toward IL-12 might repre-
sent an effective antitumor therapy. In murine dendritic cells, we 
demonstrated that the toll-like receptor (TLR) 9-induced IL-12/
Th1 axis is regulated by p47phox, a protein of the NADPH oxidase 
(21). With the following study, we investigated whether expression 
of p47phox influences inflammation-dependent tumor growth in 
mice. For this purpose, we established a colitis-dependent colo-
rectal cancer model (22) combined with the application of the 
TLR9 ligand CpG. Monitoring the progress of colitis and tumor 
growth with a mini-endoscope developed for mouse colonoscopy 
(23), our data clearly support the pivotal roles of IL-12 and IL-23 
and the modulation by p47phox in colon cancer.
aniMals anD MeThODs
Mice
Wild-type (WT) C57BL/6 and IL-12p35−/− mice were 
obtained from Jackson Laboratory (24). Initial breeding pairs of 
p47phox−/− transgenic mice also from Jackson Laboratory were 
kindly provided by R. Brandes and subsequently backcrossed to 
the C57BL/6 background for 10 generations (25). IL-23p19−/− 
mice were kindly provided by N. Ghilardi (Genentech) (26). 
The animals were bred and fed under pathogen-free conditions 
in secluded scantainers. All animal experiments were approved 
by the Institutional Animal Care and Use Committee of Goethe 
University Medical Faculty and the Animal Protection Agency of 
the Federal State of Hessen.
experimental Model of colitis  
and colon cancer
The inflammation-induced colon cancer mouse model as intro-
duced by Tanaka et al. was adapted to the mouse strains used in 
this study (22). Specifically, mice received a single intraperitoneal 
injection (10  mg/kg body weight) of the cancerogenic reagent 
azoxymethane (AOM, SigmaAldrich). Chronic colitis was 
induced by three cycles of 1.5% dextrane sodium sulfate (DSS, 
MP Biomedicals) in the drinking water for 1 week and normal 
drinking water for the consecutive 2  weeks. Mice received 
i.p. injections of TLR9 ligand ODN CpG2216 (25  μg/mouse, 
Invivogen) or phosphate-buffered saline (PBS) once per week. 
Every day, mice were monitored for their general condition, 
weight, feces, and bleeding. A detailed scoring protocol is shown 
in Table 1.
endoscopic Procedure and  
sample collection
At the end of the second (week 5) and third (week 8) cycles of 
DSS, mice were anesthetized and examined endoscopically with 
respect to inflammation and tumor development in the colon 
using the coloview system (23). While the colonoscopy at week 
5 was performed to control for disease progression, during the 
second colonoscopy serial high resolution micrographs covering 
the entire colon were recorded, and severity of inflammation and 
tumor growth was numerically scored in a blinded fashion with a 
scoring system described previously and represented in Tables 1 
and 2 (23, 27). Finally, mice were sacrificed, the colon was dis-
sected and washed with PBS, and samples for RNA, protein, and 
histology were taken. Discrimination of tumor and inflamed 
tissue based on the recorded colonoscopy pictures. Samples for 
RNA isolation were stored in RNA later (Qiagen) at 4°C until 
their use. Tissue samples for protein isolation were immediately 
frozen in liquid nitrogen and stored at −80°C. Histology samples 
were frozen and stored at −80°C.
allogeneic bone Marrow Transplantation
Bone marrow cells were isolated from femurs and tibiae of donor 
WT and IL-23p19−/− mice by flushing the bones with PBS 
Table 3 | Transplantation scheme.
recipient Donor
Wild-type (WT) interleukin (il)-23p19−/−
WT ✓ ✓
IL-23p19−/− ✓ ✓
Table 4 | Target genes and their corresponding gene expression assays.
gene of interest TaqMan® gene expression assay iD number
Interleukin (IL)-23p19 Mm00518984_m1
IL-12p35 Mm00434165_m1
IL-12/23p40 Mm01288993_m1
IL-17A Mm00439619_m1
18s Hs03003631_g1
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containing 0.5% BSA (Sigma Aldrich). Bone marrow cells were 
counted and the hematological profile was determined (Hemavet 
950FS; Drew Scientific). Groups of WT and IL-23p19−/− mice 
(aged 10 weeks) were irradiated (9.5 Gy) and within 1 h 1 × 106 
bone marrow cells in 200 µl PBS were injected intravenously into 
the tail vein. The transplantation scheme (donor and recipient) is 
shown in Table 3. Transplanted mice received antibiotic treatment 
(0.025% Baytril, Bayer HealthCare) in the drinking water and 
jelly food for 10 days after transplantation and were monitored 
at least daily. Mice with >15% weight loss received systemic fluid 
supplementation with 300  µl warmed Sterofundin G (B Braun 
Melsungen AG) given as i.p. bolus. Following confirmation of a 
full immune reconstitution, the DSS/AOM experiment was initi-
ated 16 weeks after transplantation.
rna isolation and Quantitative  
real-time Pcr
RNA from colon tissue samples was isolated using the RNeasy 
Mini Kit (Qiagen, Hilden, Germany) and the concentration of 
RNA was determined photometrically. Synthesis of cDNA was 
performed with the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems) using random hexamers and 0.5  µg 
of total RNA according to the manufacturer’s instructions. 
Expression of mRNA was analyzed using specific TaqMan® 
Gene Expression Assays containing 20× pre-formulated prim-
ers and 5′FAM-labeled probes (Table  4; Applied Biosystems). 
Quantitative real-time PCRs were performed in triplicates with 
5 µl AbsoluteFast QPCR LowROX Master Mix (ABgene), 3.5 µl 
H2O, 0.5 µl of 20× assay mix, and 1 µl cDNA with the following 
cycling program: 95°C for 5  min (1×) then successively 95°C 
for 3 s and 60°C for 30 s (40×) in the 7500 Fast Real-Time PCR 
System (Invitrogen). For each gene analyzed, a normalized ratio 
was calculated using 18s RNA as a reference gene and cDNA 
from non-treated mice as control to compensate for inter-run 
differences.
Flow cytometry
Isolation of mononuclear cells from colon tumor tissue was per-
formed as described previously (28). Single cell suspension was 
washed twice in PBS with 0.5% BSA and 2 mM EDTA and stained 
with antibodies for CD45-PE-Cy7, CD11b-V500, CD11c-PerCP, 
IL-12p35-PE, and IL-23p19-APC (BD Biosciences). Flow cyto-
metric analyses were conducted using an LSR II flow cytometer 
(BD Biosciences). Data were evaluated using FlowJo software 
(Version 7.6.5; FlowJo).
immunohistochemistry
Frozen tissue samples were fixed in 3.7% formaldehyde (FA) 
overnight at 4°C, transferred into 1% FA until they were embed-
ded in paraffin. Paraffin samples were cut into 5 µm sections and 
stained with hematoxylin and eosin. Tumor grades in histological 
sections were classified into aberrant crypt foci (ACF), adenoma 
(Ad), and mucosal carcinoma. Detection of IL-23 in the tumor 
tissue was performed with an anti-IL-23p19 antibody (rabbit 
polyclonal, Abcam). Proliferating cells were detected via Ki-67 
staining with a rat monoclonal antibody (Dako). Secondary anti-
rabbit and anti-rat (Vector Laboratories, Inc.) antibodies coupled 
to biotin were added and sections were developed via the strepta-
vidin–HRP VECTASTAIN® ABC Kit (Vector Laboratories, 
Inc.). Finally, color development was performed with 3-amino-
9-ethylcarbazole (AEC; Dako). All sections were counterstained 
with Harris hematoxylin solution (Sigma Aldrich).
statistics
Unless otherwise indicated, experiments were performed at 
least three times with three to six animals per group. Data are 
presented as the mean ± SEM. Statistical significance was tested 
with Mann–Whitney U-test or conditional Wilcoxon U-test with 
P-values corrected by Holm for multiple testing.
resUlTs
il-12p35−/− Mice exhibit reduced  
colitis but increased susceptibility  
to colon cancer
Although they share a common subunit, IL-12 and IL-23 have 
divergent immunological roles regarding chronic inflammation 
and cancerogenesis. The protective role of IL-12 in cancerogen-
esis has been demonstrated in chemically or physically (UV light) 
induced or spontaneous cancer models (12, 16, 17, 29). To examine 
the role of IL-12 in colitis-associated colon cancer, we compared 
IL-12p35−/− mice with WT mice for their susceptibility to cancer 
in the DSS/AOM model. Compared to WT mice, IL-12p35−/− 
exhibited a significantly higher tumor score (Figure  1A). By 
contrast, IL-12p35−/− mice developed significantly milder DSS 
colitis compared to WT mice (Figure 1B). These data strengthen 
the protective function of IL-12 in inflammation-dependent 
colon cancer.
increased inflammation but Decreased 
Tumor growth in p47phox−/− Mice
In a previous study, we showed an increased, TLR9-induced IL-12 
response in p47phox−/− mice (21). These mice are character-
ized by a defective NADPH oxidase (nox2) system due to lack 
of p47phox which results in decreased reactive oxygen species 
FigUre 1 | Tumor and inflammation score of interleukin (il)-12p35−/− and wild-type (WT) mice. IL-12p35−/− and WT mice were investigated in the DSS/
AOM model. (a) Tumor score and (b) inflammation score of IL-12p35−/− and WT mice were determined by colonoscopic examination. Representative endoscopic 
pictures are shown (Tu, tumor; Th, thickening of the colon; Gr, granularity of the mucosal surface; Fi, fibrin; Vasc, vascularization). Results are mean ± SEM of at 
least six mice per group. Statistical significance is indicated (*P < 0.05; **P < 0.01).
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and increased inflammation. In order to prove whether the 
augmented IL-12/Th1 axis may influence tumor development, we 
investigated p47phox−/− and WT mice in the DSS/AOM tumor 
model. During endoscopic examination of mice, we detected a 
decreased tumor score in p47phox−/− mice (6.0 ± 1.58, n = 8; 
Figure 2A) compared to WT mice (9.43 ± 2.26, n = 7; Figure 2A). 
By contrast, the inflammation score was increased in p47phox−/− 
mice (3.5 ± 1.04, n = 8; Figure 2B) in comparison to WT mice 
(1.43 ±  0.37, n =  7; Figure  2B). Investigating the influence of 
TLR9-dependent activation of immune cells during the tumor 
development, mice were treated with CpG ODN 2216 (CpG). 
Application of CpG suppressed the tumor development in WT 
and p47phox−/− mice compared to the PBS group (Figure 2C vs. 
Figure 2A). Nevertheless, tumor scores were significantly lower 
in CpG-treated p47phox−/− mice (3.71 ± 1.25, n = 7; Figure 2C) 
compared to WT (6.75 ± 2.24, n = 8; Figure 2C). However, in CpG-
treated p47phox−/− mice, we detected a significant enhanced 
inflammation score compared to WT mice (p47phox−/−: 
5.38 ± 1.41, n = 7; WT: 0.88 ± 0.44, n = 8; Figure 2D). Weight loss, 
a characteristic albeit unspecific symptom of colitis, was monitored 
in detail during the third DSS cycle (chronic inflammation). A 
few days after the final DSS application, we quantified the weight 
loss. Between non-treated (PBS) WT and p47phox−/− animals 
no weight difference was detected (Figure 2E). By contrast, we 
observed a higher weight loss in CpG-treated p47phox−/− mice 
compared to WT mice (Figure 2F).
Tumor-Promoting il-23/il-17 axis is 
impaired in p47phox−/− Mice
Based on endoscopic analyses, we wanted to know which 
inflammatory and tumor-promoting cytokines are involved. We 
analyzed the mRNA of tumor and inflamed colon tissue from 
WT and p47phox−/− mice treated with or w/o CpG. In both 
WT and p47phox−/− mice, we detected a significantly increased 
IL-23p19 mRNA expression in tumor tissue compared to 
inflamed tissue (Figure 3A). Moreover, tumor samples from WT 
mice showed significantly higher expression of IL-23p19 mRNA 
when compared with their p47phox−/− littermates (Figure 3A). 
IL-23 drives the cytokine IL-17, which is also associated with 
tumorigenesis. We detected an increased IL-17 mRNA expression 
in tumor tissue compared to inflamed tissue (Figure 3B). As seen 
for IL-23p19, we also found significantly higher IL-17 mRNA 
expression in WT tumor tissue compared to p47phox−/− mice. 
Treatment with CpG did not significantly influence IL-23p19 or 
IL-17 mRNA expression (Figures 3A,B).
Based on our previously published data, that CpG-induced 
IL-12 is significantly increased in p47phox−/− dendritic cells, 
we investigated the expression of IL-12 during colitis-associated 
colon cancer. In contrast to IL-23p19, we did not detect sig-
nificant differences for IL-12p35 mRNA expression between 
WT and p47phox−/− mice (Figure 3C). Interestingly, compared 
to inflamed tissue, IL-12p35 mRNA is significantly increased 
in tumor tissue of WT mice that were not treated with CpG 
(Figure 3C).
The common IL-12 and IL-23 subunit p40 exhibited no 
difference in the mRNA expression level between tumor and 
inflamed tissue (Figure  3D). Nevertheless, in inflamed tissue 
p47phox−/− mice expressed significantly less IL-12p40 mRNA 
compared to WT mice (Figure  3D). In summary, our data 
revealed a significantly impaired IL-23/IL-17 axis in tumor tissue 
of p47phox−/− mice.
lower Tumor grades in p47phox−/− Mice 
and the correlation with il-23 Protein 
expression
Our endoscopic evaluation showed that p47phox−/− mice 
generally exhibit lower tumor scores. Compiling and sorting 
all tumors prepared from colons of WT and p47phox−/− mice 
related to their size, we observed that p47phox−/− mice develop 
equal numbers of grade 1 and 2 tumors, but fewer grade 3 and 
4 tumors than WT mice (Figure 4A). In colon sections, stained 
with H&E, we detected different tumor grades. In contrast to 
FigUre 2 | Tumor and inflammation score of p47phox−/− and wild-type (WT) mice treated with or w/o toll-like receptor 9 ligand cpg. (a) Tumor score 
and (b) inflammation score of p47phox−/− and WT mice, determined by colonoscopic examination. (c) Tumor score and (D) inflammation score of p47phox−/− 
and WT mice, weekly treated with 25 µg CpG2216. (e,F) Weight development of mice treated w/o (e) and with CpG (F) during and after the third DSS cycle as 
percentage of starting weight. The DSS cycle is marked in gray. (a–F) Results are mean ± SEM of three independent experiments with at least seven mice per 
group. Statistical significance is indicated (*P < 0.05; **P < 0.01; ***P < 0.001).
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WT mice, p47phox−/− mice develop some more ACF, but 
significantly fewer Ad and specifically after CpG treatment no 
MC (Figure  4B). Recently, it has been shown that IL-23p19 
mRNA expression is strongly upregulated in human and mouse 
colorectal cancer (13, 14, 16). To prove whether IL-23 expression 
correlates with the tumor grade, we stained colon sections from 
WT mice for IL-23p19 protein. We could hardly detect IL-23p19 
in ACF (Figure  4C). By contrast, IL-23 expression increased 
with the tumor grade (Figure 4C). In detail, Ad and MC tissue 
exhibited dramatically increased IL-23p19 protein (Figure 4C). 
In parallel, we stained the sections for Ki-67 to detect the pro-
liferating cells within the different tumor stages (Figure 4C). To 
determine the cell source of IL-23 in tumor tissue, we isolated 
mononuclear cells from tumor and tumor-free tissue and ana-
lyzed them for the cytokines IL-23 and IL-12 (Figure 4D). We 
detected in CD11b+CD11c+ myeloid cells, isolated from colon 
tumors high level of IL-23 (Figure 4D, left). In contrast to WT 
cells, p47phox−/− myeloid cells produce less IL-23 in tumor tis-
sue. In tumor-free tissue, only a few myeloid cells secrete IL-23 
independent of the genetic background. In contrast to IL-23, 
IL-12 was slightly increased in p47phox−/− myeloid cells, but 
no significant difference could be observed (Figure 4D, middle). 
Furthermore, we measured equal numbers of myeloid cells in 
tumor tissue between WT and p47phox−/−, whereas in tumor-
free tissue from p47phox−/− PBS-treated mice, the percentage 
of myeloid cells was significantly increased (Figure 4D, right).
allogeneic Transplantation of il-23p19−/− 
bone Marrow cells Protected WT  
Mice against colon cancer in a  
Tlr9-Dependent Manner
In the tumor microenvironment, tumor-infiltrating CD11b+ 
or F4/80+ myeloid cells appear to be the main source of IL-23 
(16). In our model, the source of IL-23 in tumor tissue are 
CD11b+CD11c+ myeloid cells (Figure  4D). Using a lethal 
irradiation/bone marrow transplantation approach, with 
isogeneic WT or IL-23p19−/− hosts and WT or IL-23p19−/− 
donor hematopoietic cells, we sought to address whether bone 
marrow-derived myeloid cells infiltrate colon tissue and influence 
TLR9-dependently chronic inflammation and tumor progression 
in the colon.
As expected from previous publications, IL-23p19−/− bone 
marrow-transplanted IL-23p19−/− mice showed decreased 
FigUre 3 | expression of interleukin (il)-12, il-23, and il-17 mrna in tumor and inflamed tissue of p47phox−/− and wild-type (WT) mice.  
(a) Expression of IL-23p19, (b) IL-17, (c) IL-12p35, and (D) IL-12/23p40 mRNA in tumor and inflamed tissue from p47phox−/− and WT mice treated with or w/o 
CpG was determined by quantitative real-time PCR. Results are mean ± SEM and representative of three independent experiments with n = 12–22 samples. 
General differences between p47phox−/− and WT mice were tested for statistical significance (*P < 0.05; **P < 0.01). Differences between tumor and inflamed 
tissue from p47phox−/− and WT mice, respectively, were tested for statistical significance (#P < 0.05; ##P < 0.01; and ###P < 0.001).
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tumor growth in comparison to WT animals reconstituted 
with WT cells (Figure  5A, white vs. black bars). Treatment 
with TLR9 ligand CpG2216 did not influence the tumor score 
in WT/WT or IL-23p19−/−/IL-23p19−/− mice (Figure  5C). 
Interestingly, WT mice, transplanted with bone marrow cells 
from IL-23p19−/− mice have lower tumor scores compared to 
WT controls (Figure  5A, black-white hatched vs. black bars) 
and were protected from tumor growth after CpG treatment 
(Figure 5C, black-white hatched bar), i.e., showed the same phe-
notype as IL-23p19−/−/IL-23p19−/− mice. Correspondingly, 
transplantation of WT bone marrow cells into IL-23p19−/− 
mice resulted in increased tumor growth which became 
significant when mice were treated with CpG (Figures  5A,C, 
black dotted bars), indicating that hematopoietic cell-intrinsic 
effects mediate the promotion of tumor growth in our model. 
While we observed no differences in the inflammation score 
between WT and IL-23p19−/− mice (Figure 5B), CpG-treated 
IL-23p19−/− showed increased inflammation compared to WT 
mice (Figure 5D). Transplantation of WT bone marrow cells into 
IL-23p19−/− mice resulted in significantly enhanced inflamma-
tion compared to WT/WT (Figures 5B,D, black-white hatched 
bars). By contrast, WT mice transplanted with IL-23p19−/− 
bone marrow showed significantly less inflammation compared 
to IL-23p19−/− mice with WT hematopoiesis (Figure 5D).
In summary, ablation of IL-23p19 specifically in the hemat-
opoietic compartment is sufficient to replicate the anti-neoplastic 
phenotype of the IL-23p19−/− mice, while surprisingly ablation 
only in stroma had the opposite effect. Furthermore, modulation 
of TLR9 in WT mice reconstituted with IL-23p19−/− bone mar-
row cells strongly enhanced the protection against colon tumors 
and chronic inflammation.
DiscUssiOn
The cytokines IL-12 and IL-23 share the subunit p40, which 
heterodimerizes with the subunit p35 to form bioactive IL-12 
or with p19, to generate bioactive IL-23 (30). While both pro-
inflammatory cytokines are associated with autoimmune diseases 
(31, 32), the balance between IL-12 and IL-23 seems to be critical 
for the outgrowth of malignant cancer (18).
In this study, we wanted to ascertain whether the modulation 
of IL-12 and IL-23 affects carcinogenesis in the colon. In initial 
experiments, we investigated IL-12p35−/− mice for their sus-
ceptibility to colon cancer. In a colitis-associated cancer model 
(DSS/AOM model), we confirmed the data from others that IL-12 
deficiency resulted in increased tumor growth. In a previous pub-
lication, we described a negative feedback mechanism of IL-12 by 
the NADPH oxidase protein p47phox (21). These findings raised 
the question, whether the modulation of IL-12 by the p47phox 
influences the tumor development in this colitis-associated 
cancer model. Indeed, we found a decreased tumor score in 
p47phox−/− mice compared to WT mice (Figure 2A). By contrast, 
inflammation in the colon was increased in p47phox−/− mice 
(Figure 2B). Recently, more severe colitis has been demonstrated 
in the p47phox mutant strain BQ.Ncf1m1J/m1J, which we have 
investigated for the IL-12 feedback mechanism (21, 33). In our 
model, repeated cycles of DSS results in chronic colitis which 
promotes tumor development (22). Interestingly, we observed 
that inflammation in the colon is uncoupled from tumor growth 
in p47phox−/− mice. Because the balance of the two closely 
related cytokines IL-12 and IL-23 is important for the switch from 
chronic inflammation to tumorigenesis (18, 19), we wanted to 
know whether this could be an explanation for the divergence 
FigUre 4 | histological analyses of tumor tissue. (a) Numbers of tumors per tumor size calculated from seven mice per group. (b) Colon tissue sections of 
p47phox−/− and wild-type mice treated with or w/o CpG were stained with hematoxylin and eosin. Grades are indicated as aberrant crypt foci, adenoma, and 
mucosa carcinoma (MC). One representative section of three to five is shown. Statistical analysis of tumors in histological sections was performed. Results are 
mean ± SEM of three to five histological samples per group (c) Colon tissue sections were stained for interleukin (IL)-23, Ki-67, and counterstained for hematoxylin. 
For each stage, one representative section of three to five is shown. (D) Flow cytometry analysis of IL-23 and IL-12 in myeloid cells from tumor and tumor-free tissue 
was performed. Results are mean ± SEM of five to seven mice per group. Statistical significance is indicated (*P < 0.05; **P < 0.01).
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between inflammation and tumor growth in p47phox−/− mice. 
In this context, we investigated the mRNA expression of IL-12 
and IL-23 subunits. Whereas we detected high amounts of the 
IL-23 subunit p19 in tumor tissue of WT mice; in p47phox−/−, 
we observed significantly lower p19 expression (Figure  3A). 
In recent years, IL-23 has emerged as an important player in 
the development of cancer. In various human tumors, IL-23 
mRNA is increased and correlates with a bad prognosis (12, 14). 
Furthermore, the IL-23-driven cytokine IL-17, secreted by T cells 
of the innate and adaptive immune system, is strongly associ-
ated with tumor growth (34–36). In our model, we also found 
increased IL-17 mRNA expression in tumors of WT mice, but not 
in p47phox−/− mice (Figure 3B). A p47phox-dependent effect 
on IL-23/IL-17 axis in colon cancer has not been described so far. 
Evidence was provided that in human colorectal cancer, NADPH 
oxidase components p47phox and p67phox and the myeloid 
marker CD14 correlate with IL-23p19 expression levels (12). 
Defect in p47phox protein expression results in increased IL-6 and 
IL-17 expression in the chronic DSS colitis model (33). Further, 
activation of neutrophils and their infiltration into tumor tissue 
is known to be dependent on IL-23, which induces the secretion 
of IL-17 and G-CSF from activated T cells. Maintaining constant 
FigUre 5 | Tumor and inflammation score of interleukin (il)-23p19−/− (p19KO) and wild-type (WT) recipient mice. (a,b) Tumor (a) and inflammation 
(b) score of p19KO and WT mice, lethally irradiated and transplanted with bone marrow cells from p19KO and WT mice or vice versa. (c,D) Tumor (c) and 
inflammation (D) score of CpG-treated, transplanted mice. Results are mean ± SEM and n = 3–6. Statistical significance is indicated (*P < 0.05; **P < 0.01).
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numbers of circulating neutrophils in the body, dendritic cells, 
and macrophages phagocytose apoptotic neutrophils, which in 
turn inhibit the IL-23 expression of those cells (37). It should be 
mentioned that IL-23 seems to have antitumorigenic potential. 
Indeed, it has been demonstrated that systemic treatment or 
local administration of IL-23 induces antitumor immunity, but 
in contrast to endogenous IL-23 level only excessive exogenous 
doses led to an antitumorigenic response (38, 39). Furthermore, 
in ovarian cancer, it was shown that high intra-tumoral IL-23p19 
mRNA levels correlate with a better outcome of the disease (40). 
Interestingly, the authors figured out that high IL-23p19 mRNA 
expression only improves the survival in early stages of cancer, 
whereas in late stages high IL-12p35 mRNA is associated with a 
better outcome.
In our previous study, we demonstrated TLR9-dependent 
IL-12/Th1 regulation by p47phox (21). To investigate the effect of 
TLR9 activation, we treated the mice with TLR9 ligand CpG2216 
in the DSS/AOM model. Although CpG treatment reduced tumor 
scores in both, p47phox−/− and WT mice, the lack of p47phox 
resulted in a significantly enhanced protection against colon can-
cer development (Figure 2C). By contrast, CpG treatment caused 
increased inflammation in p47phox−/− mice (Figure 2D), which 
confirms previous data from inflammation models (41–43). 
Moreover, we measured a higher, although not significant 
IL-12p35 mRNA expression in tumor and inflamed tissue from 
p47phox−/− mice compared to WT mice (Figure  3C). These 
data support the hypothesis that p47phox-dependent regulation 
of TLR9-induced IL-12 might be involved in the modulation of 
the immune response during tumorigenesis. It was shown that 
IL-23 is the driving cytokine in intestinal inflammation, whereas 
IL-12 seems to have a more systemic impact (44). In a recent 
study, using IL-23p19 deficient mice on a dominant negative 
TGFβ receptor background, it was demonstrated that colon 
inflammation is IL-23 dependent, but the driving activity for 
liver inflammation is limited to the IL-12/Th1 axis (45). Although 
many studies investigated the impact of IL-12 and IL-23 during 
intestinal inflammation, the exact interaction mechanism of 
these cytokines remains undefined.
In our study, we detected that p47phox deficient mice gener-
ally have lower tumor scores. Interestingly, compared to WT mice 
they developed similar numbers of low grade tumors (size 1), but 
fewer high grade tumors (size 3–4; Figure 4A). On histological 
level, p47phox−/− mice develop some more ACF, but significantly 
fewer Ads (Figure 4B). Furthermore, with increasing malignancy 
(from ACF to MC), we found progressively elevated levels of 
IL-23p19 protein in colon sections (Figure 4C). Together with 
the significantly reduced IL-23p19 mRNA in tumor samples of 
p47phox−/− mice, we hypothesize that a p47phox-dependent 
mechanism, e.g., IL-12/Th1 regulation, shifts the immune bal-
ance toward colorectal cancer.
Tumor-infiltrating myeloid cells were previously postulated 
to be the prime source of IL-23 (16). We confirmed these data 
by analysis of IL-23 in myeloid cells from tumor and tumor-free 
tissue (Figure 4D). To directly assess this, as well as to address 
a possible adjunct role of stroma-derived IL-23, the colitis-
associated colon cancer model was also tested in WT mice 
stably reconstituted with IL-23p19−/− hematopoiesis and in 
IL-23p19−/− mice reconstituted with WT hematopoietic cells. 
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IL-23p19−/− to IL-23p19−/− and WT to WT transplantation 
experiments served as controls, i.e., to address whether lethal 
irradiation and bone marrow transplantation would affect the 
course of colitis and tumorigenesis. This was not the case, as 
either recipient groups responded with the same phenotype 
as non-transplanted IL-23p19−/− or WT mice, respectively. 
Mice exclusively deficient for IL-23p19 in their hematopoietic 
system reproduced the phenotype of IL-23p19−/− complete 
knock-out mice, including the observation that after CpG, the 
hematopoietic ablation of IL-23p19 strongly attenuated tumor 
induction, supporting the paradigm mentioned above that the 
hematopoietic origin of IL-23 is the decisive enhancer of tumor 
growth (Figure  5). By contrast, IL-23-p19−/− mice bearing 
WT hematopoietic cells were characterized by a markedly 
increased colitis, without any effect on the colon tumor score 
(Figure 5). This observation suggests differential, cell-context-
dependent roles of IL-23 on inflammation and tumorigenicity. 
Several studies imply a separate intestinal function of IL-23/
Th17 and IL-12/Th1 in vivo, but a recent study demonstrated 
that Th17 cells convert into Th1 cells promoted by mucosa-
derived IL-12 and IL-23 (46). In contrast to this cooperation 
between IL-12 and IL-23 during colon inflammation, the 
divergence of both cytokines is critical for the initiation of 
colon cancer (18).
In conclusion, our study revealed a novel p47phox-dependent 
regulation of the IL-23/Th17 axis during colon cancerogenesis. 
Together with the finding that p47phox regulates TLR9-induced 
IL-12 expression in myeloid dendritic cells; targeted manipula-
tion of p47phox protein would be a promising strategy to shift the 
IL-12/IL-23 balance into an antitumorigenic direction.
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